Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cabozantinib in Advanced Renal-cell Carcinoma

Comparing it with everolimus

Publish date:: October 6, 2015

Progression-free survival was longer with cabozantinib than with everolimus among patients with renal-cell carcinoma (RCC) that had progressed after VEGFR-targeted therapy, according to a study of 658 patients with metastatic renal-cell carcinoma. Researchers found:

• Median progression-free survival was 7.4 months with cabozantinib vs 3.8 months with everolimus.

• Rate of progression or death was 42% lower with cabozantinib.

• Objective response rate was 21% with cabozantinib vs 5% with everolimus.

• Adverse events were managed with dose reductions; doses were reduced in 60% of patients receiving cabozantinib vs 25% receiving everolimus.

• Treatment discontinuation occurred in 9% of patients receiving cabozantinib vs 10% receiving everolimus.

Citation: Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. [Published online ahead of print September 25, 2015]. N Engl J Med. doi: 10.1056/NEJMoa1510016.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Genitourinary Cancer

Study shows no link between race and mortality in clear cell RCC,

Four factors may predict better survival with cabozantinib in mRCC,

Focal radiation boost nets better outcomes in prostate cancer,

Fear of recurrence highly prevalent in RCC survivors,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,